养血祛瘀方联合ARB/ACEI对糖尿病肾病患者尿蛋白治疗作用观察

doi:10.3969/j.issn.1000-8535.2016.02.007

广州医药 ›› 2016, Vol. 47 ›› Issue (2): 21-23.DOI: 10.3969/j.issn.1000-8535.2016.02.007

养血祛瘀方联合ARB/ACEI对糖尿病肾病患者尿蛋白治疗作用观察

王安¹, 章秋², 方朝晖³, 刘会前¹

1 南京鼓楼医院集团安庆市石化医院 (安庆 246001)
2 安徽医科大学第一附属医院(合肥 230031)
3 安徽中医药大学第一附属医院(合肥 230031)

收稿日期:2015-12-30 出版日期:2016-03-20 发布日期:2021-11-30
通讯作者: 章秋,E-mail:13965015060@163.com
基金资助:
安庆市临床医学重点学科建设计划资助项目(2013040)

Observation of the clinical effects of Yang Xue Qu Yu Fang combined with ARB/ACEI on urinary albumin excretion in patients with diabetic nephropathy

Wang An, Liu Huiqian, Zhang Qiu, Fang Zhaohui

Wang An, Liu Huiqian. Anqing Shihua Hospital of Nanjing Drum Tower Hospital Group, Anqing, Anhui 246001,China
Zhang Qiu. The First Affiliated Hospital of Anhui Medical University,Hefei 230031,China
Fang Zhaohui. The First Affiliated Hospital of Anhui university of Chinese medicine, Hefei 230031,China

Received:2015-12-30 Online:2016-03-20 Published:2021-11-30

摘要/Abstract

摘要： 目的观察养血祛瘀方联合血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB)类药物对糖尿病肾病不同分期的疗效。方法 134例糖尿病肾病患者采用随机区组设计方案,以初诊时间(月份)作为配伍因素,随机分为治疗组67例和对照组67例,两组均采用常规西医综合基础治疗,对照组给予ACEI或ARB类药物治疗,治疗组在对照组治疗的基础上联用养血祛瘀方治疗,观察60 d,分析两组治疗前后24h尿微量白蛋白、24 h尿蛋白定量、血清C反应蛋白(hs-CRP)的变化。结果对于糖尿病肾病Ⅲ期患者,治疗组较对照组尿蛋白减少,但差异无统计学意义(P＞0.05),治疗组较对照组hs-CRP水平明显下降(P＜0.05);对于糖尿病肾病Ⅳ期患者,治疗组较对照组尿蛋白减少(P＜0.05),治疗组较对照组hs-CRP水平下降(P＜0.05)。结论养血祛瘀方联合ACEI或ARB类药物可有效减少糖尿病肾病Ⅳ期患者蛋白尿,降低糖尿病肾病患者hs-CRP水平。

关键词: 养血祛瘀方, 糖尿病肾病, 血管紧张素转换酶抑制剂, 血管紧张素受体拮抗剂

Abstract: Objective To investigate the efficacy of Yang Xue Qu Yu Fang combined with ARB/ACEI on different stages of diabetic nephropathy. Mehtods 134 patients who suffered from diabetic nephropathy were randomly divided into observation group and control group, each of them had 67 cases. The experiment use randomized block design and choose the time (months) of initial diagnosis as the compatibility factors. Both groups were treated by conventional therapy. The control group was given medicine of ARB/ACEI while the observation group was added Yang Xue Qu Yu Fang on the basis of control group. We observed all the patients for 60 days, to compare the microalbuminuria in urine of 24h, the urinary protein of 24h and the serum high sensitive C-reaction protein (Hs-CRP) between two groups before and after treatment. Results For patients of the 3rd stage of diabetic nephropathy, the albuminuria in observation group decreased obviously, but there was no significant difference between two groups (P>0.05), the serum Hs-CRP in observation group decreased obviously (P<0.05). For patients of the 4rd stage of diabetic nephropathy, the albuminuria in observation group decreased obviously (P<0.05), the serum Hs-CRP in observation group decreased obviously (P<0.05). Conclusion The Yang Xue Qu Yu Fang combined with ARB/ACEI can effectively reduce the albuminuria and can obviously lower the Hs-CRP level in the patients of the 4rd stage of diabetic nephropathy.

Key words: Yang Xue Qu Yu Fang, Diabetic nephropathy, Angiotensin-converting enzyme inhibitors, Angiotensin receptor blockers

王安, 章秋, 方朝晖, 刘会前. 养血祛瘀方联合ARB/ACEI对糖尿病肾病患者尿蛋白治疗作用观察[J]. 广州医药, 2016, 47(2): 21-23.

Wang An, Liu Huiqian, Zhang Qiu, Fang Zhaohui. Observation of the clinical effects of Yang Xue Qu Yu Fang combined with ARB/ACEI on urinary albumin excretion in patients with diabetic nephropathy[J]. Guangzhou Medical Journal, 2016, 47(2): 21-23.

参考文献

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[S]. 北京:北京大学医学出版社,2014:37-38.
[2] 范文君,祝菁菁,黄韻宇,等.我国糖尿病肾病的流行现状及其危险因素[J]. 中国慢性病预防与控制,2013,21(6):748-751.
[3] 刘会前,何晓旋,陆昌玲.保肾灵I号的研制及临床应用[J]. 时珍国医国药,2003,14 (10):610-611.
[4] 刘会前. HPLC法测定保肾灵Ⅰ号中大黄素和大黄酚的含量[J]. 重庆医学,2005,34(11):1703-1704.
[5] 陈锁胜,刘子永,严建伟.厄贝沙坦联合阿托伐他汀对早期糖尿病肾病患者血清炎症因子的影响[J]. 现代医院,2014,14(1):26-28.
[6] EURICH DT, MAJUMDAR SR, TSUYUKI RT, et al. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes[J].Diabetes Care, 2004, 27(6): 1330-1334.
[7] IMAI E, CHAN JC, ITO S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study[J].Diabetologia,2011, 54(12): 2978-2986.
[8] 张洋,马坤岭,刘晶,等.慢性炎性反应对糖尿病肾病的促进作用[J].中华肾脏病杂志,2013,29(9):681-686.
[9] 陈好利,万毅刚,赵青,等.糖尿病肾病肾组织炎症信号通路p38MAPK的调节机制及中药的干预作用[J]. 中国中药杂志,2013,38(14):2268-2272.
[10] 黄淼,马健,杨翠华,等.大黄酸对db/db小鼠胰岛功能及炎症氧化损伤标志物表达的影响[J]. 中国药物与临床,2013,13(8):976-979.
[11] 季亢挺,胡建坚,陈军,等.黄芪甲苷对氧化低密度脂蛋白诱导内皮祖细胞炎症损伤的保护作用[J]. 中国现代应用药学,2013,30(8):827-832.
[12] 李新杰,王金海,周玉森,等. 2型糖尿病肾病相关危险因素分析[J]. 安徽医学,2015,36(7):848-851.
[13] 鹿斌,杨叶红,杨志红,等.上海中心城区2型糖尿病患者高敏C反应蛋白与白蛋白尿相关性研究[J]. 中华糖尿病杂志,2011,3(1):37-41.
[14] 韦凌云,杨丕坚,李舒敏,等.炎症及内皮功能障碍与糖尿病肾病患者尿蛋白的相关性[J]. 中国老年学杂志,2014,34(9):2445-2447.

养血祛瘀方联合ARB/ACEI对糖尿病肾病患者尿蛋白治疗作用观察

Observation of the clinical effects of Yang Xue Qu Yu Fang combined with ARB/ACEI on urinary albumin excretion in patients with diabetic nephropathy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价